Diligence memo · auto-generated · as of July 2, 2026
SISCAPA Assay Technologies, Inc.
SISCAPA Assay Technologies, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
SISCAPA Assay Technologies, Inc. operates in Biotechnology, based in WASHINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
SISCAPA Assay Technologies, Inc. has raised $3.6M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.0M on 2025-04-29.
Most recent recorded round closed around 2025-04-29.
Valuation (modeled)modeled
Provath models SISCAPA Assay Technologies, Inc. at approximately $6.1M (range $1.4M–$13M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.34× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era. Within the normal band (134% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 76 months.
Last raise 14 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 37% of Biotechnology peers (4293 compared).
Modeled value ranks above 13% of those peers.
Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.